Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4277-4288

  Cai, Dawei ^a   Mills, Courtney ^b   Yu, Wenquan ^b   Yan, Ran ^a   Aldrich, Carol E ^c   Saputelli, Jeffry R ^c   Mason, William S ^c   Xu, Xiaodong ^b   Guo, Ju Tao ^a   Block, Timothy M ^a,b   Cuconati, Andrea ^b   Guo, Haitao ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BARUCH S BLUMBERG INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCC 0346; CCC 0975; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; DEPROTEINIZED RELAXED CIRCULAR DNA; SULFONAMIDE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DNA REPLICATION; DNA SYNTHESIS; DRUG IDENTIFICATION; DUCK; ENZYME ACTIVITY; ENZYME ASSAY; HEPATITIS B; HEPATITIS B VIRUS; IN VITRO STUDY; LIVER CELL; MOLECULAR LIBRARY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCREENING;

ACETAMIDES; ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; CELL LINE; DNA REPLICATION; DNA, CIRCULAR; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DUCKS; HEP G2 CELLS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B VIRUS, DUCK; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIDINES; SULFONAMIDES; THIAZOLES; VIRUS REPLICATION;

EID: 84864378861     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00473-12     Document Type: Article

References (48)

1. Block TM, Guo H, Guo JT. 2007. Molecular virology of hepatitis B virus for clinicians. Clin. Liver Dis. 11:685-706, vii. (Pubitemid 350019022)
2. Chou YC, et al. 2005. Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circularDNAby reverse transcription-PCR combined with the restriction enzyme digestion method. J. Virol. 79:1813-1823.
3. Cortes Ledesma F, El Khamisy SF, Zuma MC, Osborn K, Caldecott KW. 2009. A human 5=-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 461:674-678.
4. Dandri M, Petersen J. 2012. Chimeric mouse model of hepatitis B virus infection. J. Hepatol. 56:493-495.
5. Galibert F, Mandart E, Fitoussi F, Charnay P. 1979. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 281:646-650. (Pubitemid 10249039)
6. Gao W, Hu J. 2007. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J. Virol. 81:6164-6174. (Pubitemid 46878023)
7. Gish RG, et al. 2007. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133:1437-1444. (Pubitemid 350029745)
8. Gripon P, et al. 2002. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. U S A. 99:15655-15660. (Pubitemid 35403987)
9. Guidotti LG, et al. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829. (Pubitemid 29291352)
10. Guo H, Aldrich CE, Saputelli J, Xu C, Mason WS. 2006. The insertion domain of the duck hepatitis B virus core protein plays a role in nucleocapsid assembly. Virology 353:443-450. (Pubitemid 44397140)
11. Guo H, et al. 2007. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J. Virol. 81:12472-12484.
12. Guo H, Mao R, Block TM, Guo JT. 2010. Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J. Virol. 84:387-396.
13. Guo H, et al. 2005. Identification and characterization of avihepadnaviruses isolated from exotic anseriformes maintained in captivity. J. Virol. 79:2729-2742. (Pubitemid 40270551)
14. Guo H, et al. 2007. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J. Virol. 81:10072-10080. (Pubitemid 350067711)
15. Hirt B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
16. Hoofnagle JH, di Bisceglie AM. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
17. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. 2007. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45:1056-1075. (Pubitemid 46646501)
18. Ito K, Kim KH, Lok AS, Tong S. 2009. Characterization of genotypespecific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J. Virol. 83:3507-3517.
19. Kann M, Schmitz A, Rabe B. 2007. Intracellular transport of hepatitis B virus. World J. Gastroenterol. 13:39-47. (Pubitemid 46165461)
20. Köck J, et al. 2010. Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog. 6:e1001082. doi:10.1371/journal.ppat.1001082.
21. Kulkarni K, Jacobson IM, Tennant BC. 2007. The role of the woodchuck model in the treatment of hepatitis B virus infection. Clin. Liver Dis. 11:707-725, vii. (Pubitemid 350019031)
22. Ladner SK, et al. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1715-1720. (Pubitemid 27339873)
23. Liang TJ. 2009. Hepatitis B: the virus and disease. Hepatology 49:S13-S21.
24. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26. (Pubitemid 33653411)
25. Lok AS. 2009. Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet? J. Hepatol. 51:416-418.
26. Mason WS, Taylor JM. 1989. Experimental systems for the study of hepadnavirus and hepatitis delta virus infections. Hepatology 9:635-645. (Pubitemid 19094590)
27. McMahon BJ. 2005. Epidemiology and natural history of hepatitis B. Semin. Liver Dis. 25(Suppl 1):3-8. (Pubitemid 41254588)
28. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63. (Pubitemid 14203433)
29. Nassal M. 2008. Hepatitis B viruses: reverse transcription a different way. Virus Res. 134:235-249.
30. Newbold JE, et al. 1995. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J. Virol. 69:3350-3357.
31. Pawlotsky JM, et al. 2008. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 134:405-415.
32. Pollicino T, et al. 2006. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130:823-837. (Pubitemid 43374531)
33. Pugh JC, Summers JW. 1989. Infection and uptake of duck hepatitis B virus by duck hepatocytes maintained in the presence of dimethyl sulfoxide. Virology 172:564-572. (Pubitemid 19255975)
34. Rabe B, Vlachou A, Pante N, Helenius A, Kann M. 2003. Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc. Natl. Acad. Sci. U S A. 100:9849-9854. (Pubitemid 37087030)
35. Schmidt K, Korba B. 2000. Hepatitis B virus cell culture assays for antiviral activity. Methods Mol. Med. 24:51-67.
36. Schulze-Bergkamen H, et al. 2003. Primary human hepatocytes-a valuable tool for investigation of apoptosis and hepatitis B virus infection. J. Hepatol. 38:736-744. (Pubitemid 36613338)
37. Seeger C, Mason WS. 2000. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64:51-68. (Pubitemid 30143840)
38. Sells MA, Chen M, Acs G. 1987. Production of hepatitis B virus particles in hepG2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA. 84:1005-1009. (Pubitemid 17031557)
39. Sells MA, Zelent AZ, Shvartsman M, Acs G. 1988. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J. Virol. 62:2836-2844.
40. Sohn JA, Litwin S, Seeger C. 2009. Mechanism for CCC DNA synthesis in hepadnaviruses. PLoS One 4:e8093. doi:10.1371/journal.pone.0008093.
41. Supuran CT, Innocenti A, Mastrolorenzo A, Scozzafava A. 2004. Antiviral sulfonamide derivatives. Mini Rev. Med. Chem. 4:189-200. (Pubitemid 38854865)
42. Wang J, Lee AS, Ou JH. 1991. Proteolytic conversion of hepatitis B virus e antigen precursor to end product occurs in a postendoplasmic reticulum compartment. J. Virol. 65:5080-5083.
43. Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV. 2004. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc. Natl. Acad. Sci. U S A. 101:2129-2134. (Pubitemid 38229026)
44. Yang W, Mason WS, Summers J. 1996. Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver. J. Virol. 70:4567-4575. (Pubitemid 26187454)
45. Zhou T, et al. 2006. Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res. 72:116-124.
46. Zhu Y, et al. 2001. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J. Virol. 75:311-322.
47. Zoulim F. 2005. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J. Hepatol. 42:302-308. (Pubitemid 40254242)
48. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-1608.e1-2.